⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11479593 | 1.00 | GAA (0.70) | — | |
| SCHEMBL21678831 | 0.95 | GAA (0.78) | — | |
| SCHEMBL77344 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL29493442 | 0.82 | — | — | |
| SCHEMBL11562571 | 0.80 | GAA (0.86) | — | |
| SCHEMBL11554085 | 0.80 | GAA (0.86) | — | |
| SCHEMBL11557391 | 0.80 | GAA (0.86) | — | |
| SCHEMBL11551941 | 0.80 | GAA (0.86) | — | |
| SCHEMBL23459791 | 0.78 | — | — | |
| SCHEMBL9542421 | 0.77 | GAA (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| US-12065428-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | claimed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| WO-2024081318-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | claimed |
| WO-2024010794-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| EP-4295846-A2 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2023-12-27 | — | — | EP | claimed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | claimed |
| EP-3966206-B1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-08-09 | — | — | EP | claimed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | claimed |
| WO-2023043816-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| EP-3966206-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2020231808-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | claimed |
| EP-1706147-A2 | COMBINATION THERAPY WITH 5-HT sb 1A /sb AND 5-HT sb 1B /sb RECEPTOR ANTAGONISTS | Recordati Ireland Limited (IE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005070460-A2 | COMBINATION THERAPY WITH 5-HT1A AND 5-HT1B RECEPTOR ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2005-08-04 | — | — | WO | claimed |
| US-5349045-A | Polymer derived from cyclic amide and medical devices manufactured therefrom | UNITED STATES SURGICAL CORPORATION (US) | 1994-09-20 | — | — | US | claimed |
| US-4236028-A | BY REACTING A CARBOXYLIC ACID ANHYDRIDE, A CYANOALKOXYALKANOATE AND HEATING THE AMIDE-ESTER IN AN EXCESS OF WATER | CHEVRON RESEARCH COMPANY (US) | 1980-11-25 | — | — | US | claimed |
| US-4126614-A | OXACAPROLACTAMS | CHEVRON RESEARCH COMPANY (US) | 1978-11-21 | — | — | US | claimed |